NIHPsychiatryFunding: HMNC and the Long Road to Precision PsychiatryWith a first $50 million tranche of its Series B financing and a commercial partnership with MEDICE, HMNC Brain Health has secured fresh capital for its depression programmes. The deal marks an important … more ➔
FundraisingAplagon raises €4.8m to expand antithrombotic into new Phase II trialFinnish biotech Aplagon has raised €4.8m to broaden Phase II development of its lead candidate APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The financing … more ➔
Venture capitalKos Biotechnology raises US$123m for Greek life sciences fundKos Biotechnology Partners has raised US$123m (€106m) for its inaugural global life sciences fund, marking a notable step for Greece’s still young biotechnology financing ecosystem. more ➔
gene therapySensorion drops a gene therapy asset because of RegeneronSensorion has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as its lead gene therapy program after filing clinical trial applications in France and Canada. The French biotech … more ➔
LicensingNovartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bnOrionis and Novartis have expanded an existing deal to develop “molecular glue”, with a new agreement worth up to $1.4 billion, aiming to stick small molecule drugs onto challenging and elusive drug … more ➔
FinancingHeidelberg-based Veraxa ventures onto Nasdaq in turbulent market environmentVeraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading … more ➔
ResearchScenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’sScenic Biotech has joined the Michael J. Fox Foundation’s LRRK2 consortium to test a Parkinson’s disease approach that targets neither LRRK2 nor GCase directly. more ➔
clinical dataSanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into troubleSanofi’s $11.6bn Bioverativ acquisition is back under scrutiny after riliprubart, a rare disease drug inherited through the deal, failed a phase 3 CIDP study. While Altuviiio has become a blockbuster, … more ➔
fundraisingCircio completes NOK300m financing to fund circular RNA platform developmentOslo-based Circio has completed a NOK300m (€27m) financing round, extending its runway to the end of 2030 and giving the company funds to advance its circVec circular RNA expression platform toward … more ➔
licensingAlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bnSwedish biotech AlzeCure Pharma entered a collaboration and licensing agreement with Eli Lilly, granting the biopharma giant global rights to its Alzheimer’s disease candidate Alzstatin (ACD680). Under … more ➔
NIH
